Gantenerumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Gantenerumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target Beta-amyloid (Aβ40/42)
Clinical data
Legal status
?
Identifiers
CAS number 89957-37-9 N
ATC code None
UNII 4DF060P933 YesY
KEGG D09680 YesY
Chemical data
Formula C6496H10072N1740O2024S42 
Mol. mass 146.3 kDa (peptide)
 N (what is this?)  (verify)

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease.[1][2] A phase I clinical trial has been conducted in 2006/07.[3]

Gantenerumab is currently being evaluated in a prodromal Alzheimer's disease population in the Scarlet Road study, a global phase II study of approximately 360 subjects in 100 centers in 15 countries. [4]

One clinical study was stopped on December 19, 2014 after disappointing results.[5]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab American Medical Association.
  2. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  3. ^ ClinicalTrials.gov NCT00531804 A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease
  4. ^ http://www.scarletroadstudy.com/en-CA/index.aspx
  5. ^ http://www.nasdaq.com/press-release/morphosyss-partner-roche-provides-update-on-trial-of-gantenerumab-in-prodromal-alzheimers-patients-20141219-00045